Alex Dömling (Univ. Groningen)
The Dömling lab works for >30 years in the advancement of multicomponent reaction chemistry (MCR): novel synthesis methodologies, stereoselectivity, new chemical space, novel reactions, sustainability, and application of MCR in medicinal chemistry. As an answer to the ever-increasing humanitarian demands of society, the focus of the lab is on novel immuno oncology drugs and antibiotics, facing the rapid and global increase of multiple drug-resistant bacteria causing already now millions of deaths every year. Technologies and methods developed or used in the lab are automation and miniaturization of synthetic chemistry, structure-based drug design, fragment-based drug design, and the use of artificial intelligence methods to accelerate drug discovery.
Rapid approach to complex boronic acids Neochoritis & Shaabani et al., Science Advances 2019, 5, DOI: https://doi.org/10.1126/sciadv.aaw4607
Multicomponent reaction-derived covalent inhibitor space Sutanto & Shaabani et al., Science Advances 2021, 7,DOI: https://doi.org/10.1126/sciadv.abd9307
Tetrazoles via Multicomponent Reactions Neochoritis, Zhao, Dömling, Chem. Rev. 2019, 119, 3, 1970–2042. https://doi.org/10.1021/acs.chemrev.8b00564
Structure of the Complex of Human Programmed Death 1, PD-1, and its Ligand PD-L1 Zak et al., Structure 2015, 23, 2341-2348. https://doi.org/10.1016/j.str.2015.09.010
Chemistry and Biology of Multicomponent Reactions Wang, Wang, Dömling, Chem. Rev. 2012, 112, 3083-3135. https://doi.org/10.1021/cr100233r